These success, along with a preceding report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like actions in mice,two support the notion of targeting ACKR3 as a novel method to modulate the opioid process, which could open new therapeutic avenues for opioid-associate